TearSolutions, Inc. Announces Results from Phase I/II trial of Lacripep TM to Treat Primary Sjögren’s Syndrome and Appoints Anil Asrani President and CEO
TearSolutions, Inc. Announces Results from Phase I/II trial of Lacripep TM to Treat Primary Sjögren’s Syndrome and Appoints Anil Asrani President and CEO